High-amylose carboxymethyl starch matrices for oral sustained drug-release: in vitro and in vivo evaluation.
High-amylose corn starch, that contains 70% of amylose chains and 30% of amylopectin, has been used to obtain substituted amylose (SA) polymers. Tablets have been prepared by direct compression, i.e. dry mixing of drug and SA, followed by compression, which is the easiest way to manufacture an oral dosage form. Until now, their controlled-release properties have been assessed only by an in vitro dissolution test. Amylose-based polymers are normally subject to biodegradation by alpha-amylase enzymes present in the gastrointestinal tract, but matrix systems show no significant degradation of tablets by alpha-amylase in vitro. High-amylose sodium carboxymethyl starch (HASCA) is an interesting excipient for sustained drug-release in solid oral dosage forms. In addition to the easy manufacture of tablets by direct compression, the results show that in vitro drug-release from an optimized HASCA formulation is not affected by either acidic pH value or acidic medium residence time. In addition, a compressed blend of HASCA with an optimized quantity of sodium chloride provides a pharmaceutical sustained-release tablet with improved integrity for oral administration. In vivo studies demonstrate extended drug absorption, showing that the matrix tablets do not disintegrate immediately. Nevertheless, acetaminophen does not seem to be the most appropriate drug for this type of formulation.
Nabais
T
T
Faculty of Pharmacy, University of Montreal, Montreal, Que., Canada.
Brouillet
F
F
Kyriacos
S
S
Mroueh
M
M
Amores da Silva
P
P
Bataille
B
B
Chebli
C
C
Cartilier
L
L
D000082:Acetaminophen / Q000008:administration & dosage / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*; D000284:Administration, Oral; D000328:Adult; D000688:Amylose / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*; D002626:Chemistry, Pharmaceutical; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004339:Drug Compounding; D004355:Drug Stability; D005079:Excipients / Q000737:chemistry* / Q000378:metabolism; D005215:Fasting / Q000097:blood; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007408:Intestinal Absorption; D008297:Male; D012016:Reference Values; D012965:Sodium Chloride / Q000737:chemistry; D012995:Solubility; D013607:Tablets; D013678:Technology, Pharmaceutical; D013997:Time Factors; D000516:alpha-Amylases / Q000378:metabolism
D018712:Analgesics, Non-Narcotic; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D005079:Excipients; D013607:Tablets; C027357:carboxymethylamylose; D000082:Acetaminophen; D012965:Sodium Chloride; D000688:Amylose; D000516:alpha-Amylases